Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults: Complete Statistical AnalysisIndependent statistical analysis of GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- GRABM-LIndependent statistical analysis of GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.: Complete Statistical AnalysisIndependent statistical analysis of GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV)…
- GRAND-307Independent statistical analysis of Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes: primary endpoint results, effect estimate with…
- Granulox01Independent statistical analysis of A Multicentre European Study to Evaluate Granulox® Used in the Treatment Pathway of Predominantly Chronic Venous Leg Ulcers (VLUs).: primary endpoint results, effect estimate with confidence interval, sample-size…
- Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GRAVITYIndependent statistical analysis of 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- GRAY-BIndependent statistical analysis of GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003): Complete Statistical AnalysisIndependent statistical analysis of Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065): Complete Statistical AnalysisIndependent statistical analysis of Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- GRC00097Independent statistical analysis of Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively: primary endpoint results, effect estimate with…
- GReaTIndependent statistical analysis of Gene Regulation by Thiazolidinediones: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00567593).
- GREATIndependent statistical analysis of Get Ready And Empowered About Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02165735).
- Greater Occipital Nerve Block Versus Metoclopramide: Complete Statistical AnalysisIndependent statistical analysis of Greater Occipital Nerve Block Versus Metoclopramide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03269435).
- GRECOIndependent statistical analysis of Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Green Tea and Reduction of Breast Cancer Risk: Complete Statistical AnalysisIndependent statistical analysis of Green Tea and Reduction of Breast Cancer Risk: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00917735).
- GRIDIndependent statistical analysis of Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GRINIndependent statistical analysis of Testing Preliminary Effectiveness of a Training to Support CHWs Outreach on Dental to African American Caregivers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Group Antenatal Care: Effectiveness and Contextual Factors Linked to Implementation Success in Malawi: Complete Statistical AnalysisIndependent statistical analysis of Group Antenatal Care: Effectiveness and Contextual Factors Linked to Implementation Success in Malawi: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Group-Based Intervention to Improve Mental Health and Adherence Among Youth Living With HIV in Low Resource Settings: Complete Statistical AnalysisIndependent statistical analysis of Group-Based Intervention to Improve Mental Health and Adherence Among Youth Living With HIV in Low Resource Settings: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance: Complete Statistical AnalysisIndependent statistical analysis of Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03288103).
- Growth-TBIIndependent statistical analysis of Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00766038).
- GS2Independent statistical analysis of A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size…
- GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma: Complete Statistical AnalysisIndependent statistical analysis of GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- GSK1120212+GSK2141795 for Cervical Cancer: Complete Statistical AnalysisIndependent statistical analysis of GSK1120212+GSK2141795 for Cervical Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01958112).
- GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia: Complete Statistical AnalysisIndependent statistical analysis of GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia: primary endpoint results, effect estimate…
- GSK2251052 in the Treatment of Complicated Intra-abdominal Infections: Complete Statistical AnalysisIndependent statistical analysis of GSK2251052 in the Treatment of Complicated Intra-abdominal Infections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01381562).
- GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1): Complete Statistical AnalysisIndependent statistical analysis of GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease: Complete Statistical AnalysisIndependent statistical analysis of GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00950807).
- GSP 301-305Independent statistical analysis of Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR): primary endpoint results, effect estimate with confidence…
- GTRDOXYIndependent statistical analysis of Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01030666).
- guardian™ 3Independent statistical analysis of Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- guardian™1Independent statistical analysis of Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00840086).
- GUIDE-ITIndependent statistical analysis of Guiding Evidence Based Therapy Using Biomarker Intensified Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01685840).
- GUIDEDIndependent statistical analysis of Genomics Used to Improve DEpression Decisions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02109939).
- GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery: Complete Statistical AnalysisIndependent statistical analysis of GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Gulf War Digestive Health Study: Complete Statistical AnalysisIndependent statistical analysis of Gulf War Digestive Health Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00680836).
- Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP): Complete Statistical AnalysisIndependent statistical analysis of Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03975153).
- Gut Decontamination In Pediatric Allogeneic Hematopoietic: Complete Statistical AnalysisIndependent statistical analysis of Gut Decontamination In Pediatric Allogeneic Hematopoietic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02641236).
- Gut Organoid and Microbiome Interactions in Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Gut Organoid and Microbiome Interactions in Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04497727).
- GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- GVHD ASEDIndependent statistical analysis of A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients: primary endpoint results,…
- GWIndependent statistical analysis of Neoadjuvant GW572016 to Treat Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00206427).
- GWPCARE5Independent statistical analysis of An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Gynecological Sentinel Lymph Nodes CEUS: Complete Statistical AnalysisIndependent statistical analysis of Gynecological Sentinel Lymph Nodes CEUS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05105087).
- H2H-DFUIndependent statistical analysis of MIRODERM H2H DFU Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03232333).
- H3MIndependent statistical analysis of Healthy Hearts Healthy Minds: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03373110).
- H42/H4UIndependent statistical analysis of Pragmatic Randomized Clinical Trial to Limit Weight Gain in Pregnancy and Prevent Obesity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- HAHPSIndependent statistical analysis of Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…